SAC May Have Seen Big Profit On Drug Test News

Jan 13 2014 | 1:42pm ET

Drug trials are at the heart of the insider-trading case against a former SAC Capital Advisors trader—and have earned the hedge fund more than $200 million this year already.

SAC owned nearly 1 million shares of Intercept Pharmaceuticals at the end of September. The stock nearly tripled in value on Thursday after the company announced a positive result of a liver-disease drug.

It is unclear whether SAC still holds its Intercept shares; the firm has been returning outside capital after pleading guilty to insider-trading charges. SAC first bought Intercept shares in the second quarter, boosting its stake to more than 988,000 shares by the end of the third.

The potentially big gain would rival the amount SAC allegedly earned or saved trading on confidential tips about drug trials received by former portfolio manager Mathew Martoma. Martoma is currently on trial.


In Depth

Q&A: Star Mountain's Brett Hickey On Investing In 'The Growth Engine Of America'

Sep 22 2017 | 5:06pm ET

Lower middle-market companies form the economic fabric of the nation, but they can...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Don’t Overlook These 6 Hybrid Cloud Concerns

Sep 14 2017 | 6:27pm ET

Cloud-based technology solutions have made tremendous inroads into the alternative...

 

From the current issue of